Arbutus Biopharma Corp Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: CAD and USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Arbutus Biopharma Corp quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Arbutus Biopharma Corp Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $164M, a 12.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $164M +$18.4M +12.7% Dec 31, 2023 10-K 2024-03-05
Q4 2022 $145M +$14.6M +11.1% Dec 31, 2022 10-K 2024-03-05
Q4 2021 $131M +$15.9M +13.9% Dec 31, 2021 10-K 2023-03-02
Q4 2020 $115M +$12M +11.7% Dec 31, 2020 10-K 2022-03-03
Q4 2019 $103M +$19.1M +22.8% Dec 31, 2019 10-K 2021-03-04
Q4 2018 $83.7M +$13.1M +18.5% Dec 31, 2018 10-K 2020-03-05
Q4 2017 $70.6M +$12.1M +20.6% Dec 31, 2017 10-K 2019-03-07
Q4 2016 $58.5M +$17M +41.1% Dec 31, 2016 10-K 2018-03-16
Q4 2015 $41.5M +$3.68M +9.72% Dec 31, 2015 10-K 2017-03-22
Q4 2014 $37.8M +$37.8M Dec 31, 2014 10-K 2016-03-09
Q4 2013 $23.8K* -$15.7M Dec 31, 2013 10-K 2015-03-13
Q4 2012 $15.7M Dec 31, 2012 10-K 2014-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.